FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease

NeurologyLive·Jul 6

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has granted traditional approval to lecanemab, also known as Leqembi, for the treatment of early-stage Alzheimer's disease. This approval may impact insurance coverage, with some reports indicating that Medicare will now cover the drug. However, there is some uncertainty regarding the specifics of the approval, with one report mentioning a priority review and another discussing an accelerated approval pathway.

Full coverage

FDA Approves Leqembi for At-Home Maintenance Treatment of Alzheimer Disease

Psychiatric Times·Aug 29

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Biogen·Jul 6

With Full FDA Approval, Alzheimer’s Drug Leqembi Now Covered By Medicare

Being Patient·Aug 2

ADI - FDA converts lecanemab to traditional approval

Alzheimer's Disease International (ADI)·Jul 7

FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease

AJMC·Jan 27

Fetching the latest headlines…